Compare ACCL & FEMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACCL | FEMY |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | Hong Kong | United States |
| Employees | 22 | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 23.2M |
| IPO Year | N/A | 2021 |
| Metric | ACCL | FEMY |
|---|---|---|
| Price | $1.40 | $0.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 11.0K | ★ 388.3K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 44.71 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $2,293,313.00 |
| Revenue This Year | N/A | $105.16 |
| Revenue Next Year | N/A | $200.23 |
| P/E Ratio | $17.13 | ★ N/A |
| Revenue Growth | N/A | ★ 40.77 |
| 52 Week Low | $1.23 | $0.31 |
| 52 Week High | $5.00 | $1.11 |
| Indicator | ACCL | FEMY |
|---|---|---|
| Relative Strength Index (RSI) | 47.43 | 37.65 |
| Support Level | $1.32 | $0.33 |
| Resistance Level | $1.57 | $0.44 |
| Average True Range (ATR) | 0.06 | 0.03 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 44.19 | 6.31 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.